SCP
MYGN icon

Sender Company & Partners’s Myriad Genetics MYGN Stock Holding History

Sender Company & Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,270
Closed -$125K – 325
2025
Q3 		$125K Buy
+17,270
New +$103K 0.01% 439

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sender Company & Partners's MYGN Position: Q4 2025 in Review

Sender Company & Partners sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 17,270 shares — an estimated $125K sold.

Sender Company & Partners first reported a position in MYGN in Q3 2025 and held it in 1 quarter. The position peaked at $125K in Q3 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Sender Company & Partners reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 17,270 Myriad Genetics shares in Q4 2025, an estimated $125K.
  • Sender Company & Partners first reported a position in Myriad Genetics in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Myriad Genetics position peaked at $125K in Q3 2025.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.